A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia ® Genomic Classifier.
View HTML
Toggle Summary Veracyte to Present at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 15, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two virtual investor conferences this week: 2020 Cantor
View HTML
Toggle Summary Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it has promoted Richard T. Kloos , M.D., to executive medical director, overseeing Veracyte’s global medical affairs in all clinical areas addressed by the company’s expanding menu of
View HTML
Toggle Summary Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
PROCURE study will capture insights from 180 European breast cancer specialists, to develop consensus and recommendations SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today the initiation of a European study that will utilize the Delphi
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 4, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences: Baird’s 2020
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year.
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML
Toggle Summary Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
ePosters presented during ATS 2020 Virtual conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s
View HTML
Toggle Summary Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta ® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as
View HTML
Toggle Summary Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.
View HTML